Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
Related reading
China’s innovation paradox
Industrial policy has delivered impressive technological gains without productivity growth
China doubles down on industrial policy
Beijing should focus more on domestic demand to sustain high economic growth
For China, ‘involution’ is a blessing as well as a curse
Ferocious competition at home equips the strongest companies to prosper abroad
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
Technological sovereignty with American characteristics
The US has decided it can no longer afford to outsource its chipmaking future